Research programme: bone fracture and spinal fusion therapy - Accelalox
Latest Information Update: 21 Feb 2017
At a glance
- Originator Accelalox
- Class Small molecules
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Fracture
- Phase Unknown Spinal disorders
Most Recent Events
- 25 Jul 2016 Preclinical trials in Fracture in USA (PO)